ERBB2 and lung cancer: In gastric cancer, the elevated circ-ERBB2 enhances tumor growth and reduces overall survival in patients, and circ-ERBB2 exerts a carcinogenic effect in gastric cancer cells [8]; in lung cancer, propofol therapy represses the lung cancer cell proliferation and invasion via lessening circ-ERBB2, which provides a novel target for lung cancer treatment [9].